| Trial ID: | L3242 |
| Source ID: | NCT04706286
|
| Associated Drug: |
Ckd-501, D759, D150
|
| Title: |
Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
T2DM (Type 2 Diabetes Mellitus)
|
| Interventions: |
DRUG: CKD-501, D759, D150|DRUG: CKD-393 0.5/100/1000 mg
|
| Outcome Measures: |
Primary: AUCt(Area Under Curve last) of CKD-393, Area under the plasma concentration time curve of CKD-393, from time zero up to the last measurable concentration., From predose, upto 48 hours post-dose|Cmax of CKD-393, The maximum concentration observed of CKD-393 over blood sampling time., From predose, upto 48 hours post-dose |
|
| Sponsor/Collaborators: |
Sponsor: Chong Kun Dang Pharmaceutical
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
26
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2021-02-18
|
| Completion Date: |
2021-04-05
|
| Results First Posted: |
|
| Last Update Posted: |
2021-01-12
|
| Locations: |
Severance Hospital, Seoul, Korea, Republic of
|
| URL: |
https://clinicaltrials.gov/show/NCT04706286
|
